Table IV.

Inhibition of EAE by local administration of cytokine DNA-CLC to the CNSa

TreatmentNo. EAEMean Group Score (±SEM)Mean Day of Onset (±SEM)
CLC8/83.8 ± 0.115.0 ± 0.3
SCH23/233.7 ± 0.115.1 ± 0.3
LacZ 7/73.2 ± 0.214.7 ± 0.3
TGF-β10/152.0 ± 0.4***16.4 ± 0.5
IL-49/132.3 ± 0.4***16.2 ± 0.5b
IL-1011/113.6 ± 0.216.2 ± 0.3b
p75 dTNFR5/91.0 ± 0.3***17.2 ± 0.6**
p55 TNFR-Ig11/113.0 ± 0.3b16.4 ± 0.2***
IFN-β4/71.6 ± 0.6**14.8 ± 0.3
IFN-β [NSE]16/182.7 ± 0.3b15.4 ± 0.3
  • a Animals were injected with SCH in Freund’s adjuvant on days 0 and 7. A total of 100 μg of naked DNA coding for LacZ, TGF-β, IL-4, IFN-β, IFN-β [NSE], TNFR-Ig p55, and d-TNFR p75 were mixed with lipofectin and injected i.c. on day 12. The results represent the mean ± SEM maximum clinical score of all animals within the group and the mean day of onset of the animals that developed EAE.

  • b p < 0.05; **p < 0.01; ***p < 0.005 compared to animals injected with CLC only.